The UK and US have established a major bilateral deal that will maintain no import taxes on British drug products entering the US market.
Agreement Details of the Pact
In exchange for the tariff guarantee, the UK has committed to increase spending on drugs through the National Health Service (NHS). This commitment ensures that import taxes on these key goods will be held at nothing for a timeframe of 36 months.
This deal is in response to earlier threats to hike import taxes on patented drug imports, with figures discussed reaching double the cost.
"This agreement between the Britain reinforces the worldwide climate for innovative medicines and brings long-overdue equity to American-British pharmaceutical trade," a statement declared.
Commercial Importance
Pharmaceuticals constitute one of the the United Kingdom's biggest exports to the US, which is by far the primary market for leading UK drugmakers.
Statistics reveal that in the year leading up to the third quarter, the UK exported drugs worth billions to the US. This figure accounted for 17.4% of British export trade in that timeframe.
"This guarantee protects work, increases capital expenditure and paves the way for the UK to establish itself as a worldwide center for medical research," the Business and Trade Secretary commented.
Key British Pledges
The deal entails several specific changes from the United Kingdom:
- Revised Affordability Limit: The UK will raise the price threshold at which it deems new medicines to be unaffordable by 25%.
- Higher Drug Budget: There is a target to double total NHS spending on medicines from 0.3 percent of GDP to 0.6% over the coming ten years.
- Refund Ceiling: The amount drug companies must refund to the NHS to stay within budget will be limited at 15%. Previously, repayments were more than 20%.
Broader Context
This agreement takes place against a ongoing row between the pharmaceutical industry and the UK government over medicine costs and regulatory access.
These tensions were exacerbated by assertions that US customers were paying a premium for the equivalent treatments than patients in the Britain and the EU.
In recent months, several major drug company projects in the UK have been halted or scrapped, while substantial funding commitments have been announced toward US facilities.
A senior figure publicly accepted that the NHS needed to invest a greater share on drugs, noting that its budget allocation on drugs had decreased as a percentage of its overall budget over the previous ten-year period.
